Merck & Co. Stock News

Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript

John Buckingham, editor of the Prudent Speculator, reminds investors to be “willing to stomach volatility.”

The Magnificent 7 AI tech stocks have served as the rocket fuel propelling the S&P 500 on its bull run over the past few years.

The November 2025 high-yield dividend watchlist delivered a 2.94% gain in last month, outperforming SPY and closely trailing VYM. This watchlist blends quality and value to identify high-yield stocks with attractive valuations, aiming for a 12% long-term CAGR and strong starting yields. Top 10 picks for December include Accenture, EOG Resources, Nike, Paychex, ADP, Penske Automotive, Comcast, E...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025.

Merck is a high-yield drug stock with a well-supported dividend payment. Enbridge is a boring energy stock with a hefty yield.

One of Merck's key assets has just scored a significant phase 2 win, boosting investor confidence. This adds to other recent developments that could help the company overcome its challenges.

Merck (MRK) demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. MRK's innovation, highlighted by Keytruda's dominance and diversified revenue streams, supports strong profitability and mitigates concentration risk. MRK's proven investment track record and consistent dividend growth further reinforce its appeal as a...